We undertook this study to understand the molecular mechanisms that caused p53 underperformance compared to ANXA7 and, subsequently, to elicit the beneficial tumor suppressor mechanisms of ANXA7 in LNCaP. The gene discussed is TP53; the disease is neoplasm.